Piperacillin, a new semisynthetic piperazine derivative of ampicillin, has been demonstrated to have broad-range antibacterial activity which includes gram-negative bacilli, gram-positive cocci, and Bacteroides fragilis. Piperacillin inhibits many of the members of the Enterobacteriaceae and Pseudomonas at lower concentrations than are required for carbenicillin or ticarcillin (3) . Recently two novel ,B-lactamase inhibitors, clavulanic acid and a penicillanic acid sulfone, have become available. Both of these ,Blactamase inhibitors have been shown to be effective inhibitors of plasmid-mediated ,B-lactamases of the Richmond types II, III, IV, and V (2, 5, 7). These compounds also have been shown to act synergistically with penicillins or cephaloridine to inhibit ,B-lactamase-producing Staphylococcus aureus, Escherichia coli, Shigella sonnei, and Salmonella typhimurium. We have also shown that the cephalosporin cefotaxime is a potent inhibitor of some 8-lactamases which are chromosomally mediated by the Richmond type I (4). Although piperacillin has been shown to act synergistically against Pseudomonas and members of the Enterobacteriaceae when combined with aminoglycoside antibiotics, it is hydrolyzed by many different types of,B-lactamases (3) . It was the purpose of this study to evaluate the synergistic activity of piperacillin when combined with the /3-lactamase inhibitors against /3-lactamase-producing organisms resistant to piperacillin, and to evaluate its activity when combined with other penicillins and with cefotaxime.
MATERIALS AND METHODS
All of the organisms tested were clinical isolates from the Columbia-Presbyterian Medical Center in New York City. Piperacillin was obtained from Lederle Laboratories. Penicillanic acid sulfone and clavulanic acid were gifts from Pfizer Inc. and Beecham Laboratories, respectively, and cefotaxime was a gift from Hoechst-Roussel Inc. Synergy was determined by a checkerboard agar dilution method in Mueller-Hinton agar (6) . The inoculum was 105 colony-forming units. Synergy was defined as a fourfold or greater reduction of the minimal inhibitory concentration (MIC) of both antibiotics. Partial synergy was defined as a fourfold reduction in MIC of one agent and a two-fold reduction in MIC of the other agent, as described previously (2) . The chromogenic cephalosporin nitrocefin was used to determine the presence of ,B-lactamase in clinical isolates (8) . Classification of ,B-lactamases was based upon substrate and inhibitory profiles as determined earlier (5, 9) .
RESULTS
The combination ofpiperacilhin and clavulanic acid tested against E. coli, Klebsiella, S. aureus, Pseudomonas aeruginosa, and other members of the Enterobacteriaceae is shown in Table 1 . Piperacillin and clavulanic acid synergistically inhibited 94% of E. coli isolates that were resistant to piperacillin and 13% of the isolates that were susceptible to piperacillin. Of the E. coli isolates with a plasmid /3-lactamase activity, 64% were inhibited. All of the K. pneumoniae strains resistant to piperacillin were inhibited when it was combined synergistically with clavulanic acid, and 65% of the piperacillin-susceptible Klebsiella strains were inhibited. Of the Klebsiella strains with a plasmid ,8-lactamase, 83% were inhibited. Among the other isolates tested (35 in all), which included Citrobacter freundii, Citrobacter diversus, Enterobacter cloacae, Enterobacter aerogenes subsp. hafniae, Serratia marcescens, Proteus inconstans, Proteus mirabilis, and Morganella morganii, 85% of the piperacillin-resistant isolates were inhibited by the synergistic action of the drugs, but only 20% of the piperacillin-susceptible isolates were inhibited. Of the 23 isolates with plasmid f8-lactamases, 65% were inhibited. All of the S. aureus strains that were resistant to piperacillin, and all of the /8-lactamase-containing strains, were inhibited by the synergistic piperacillin-clavulanic acid combination. In contrast to these results, none of eight isolates of P. aeruginosa resistant to piperacillin, and only 1 of 22 isolates susceptible to piperacillin, were inhibited by the combination. None of the P. aeruginosa strains with plasmid ,8-lactamases were inhibited. The combination of clavulanic acid and piperacillin synergistically inhibited 66% of the B. fragilis subsp. isolates fragilis tested, and it also synergistically inhibited Fusobacterium.
When piperacillin was combined with penicillanic acid sulfone (Table 2 ) it synergistically inhibited 81% of the E. coli isolates resistant to piperacillin and 57% of the strains with plasmid B8-lactamases. Of the Klebsiella isolates, 31% of the piperacillin-resistant isolates and 16% of the plasmid fl-lactamase strains were inhibited by the synergistic piperacillin-penicillanic acid combination. In contrast, 87% of the Citrobacter, Enterobacter, Providencia, Proteus, and Pseudomonas isolates resistant to piperacillin were inhibited synergistically by the combination, and 92% of the plasmid 8-lactamase isolates were inhibited. The combination of penicillanic acid sulfone and piperacillin synergistically inhibited 87% of the isolates, including both constitutive and inducible 18-lactamase producers. The inhibitory concentration of piperacillin could be lowered from 128 jug/ml to 2 ,tg/ml.
A comparison of the actual inhibitory concentrations of piperacillin and the two ,8-lactamase inhibitors is given 'm Table 3 . It is clear that the clavulanic acid-piperacillin combination resulted in much lower concentrations of the compounds, and, with the exception of E. cloacae, all of the isolates were inhibited at concentrations which could readily be achieved in humans in view of the pharmacokinetics of the two agents. In general, the combination of piperacillin-clavulanic acid was eightfold more potent than piperacillin-penicillanic acid sulfone.
Piperacillin was combined with oxacillin to Resistant (8) Susceptible (22) Positive (13) Resistant (4) Susceptible (8) Positive (8) Resistant ( Piperacillin was combined with cefotaxime, which inhibits type I ,B-lactamases (4) , and tested against 29 isolates of Serratia, Enterobacter, Citrobacter, Proteus, and Pseudomonas which is a potent inhibitor of many type I ,Blactamases, did not show synergy, and antagonism was encountered with E. cloacae and P. mirabilis. Such antagonism of some of the penicillins and cephalosporins had been noted by Acar and co-workers (1) and in our earlier studies of the ureidopenicillins (6).
These observations suggest that the combination of 8-lactamase inhibitors with piperacillin will significantly extend their spectrum of activity far beyond their combination with aminoglycosides (3). Whether these in vitro observations can be translated to human infections will only be resolved by further animal and human studies. The ability to utilize two ,B-lactam agents rather than a 83-lactam and an aminoglycoside may have potential benefit, however.
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